Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 106

1.

Depression and Suicidality in Psoriasis: Review of the Literature Including the Cytokine Theory of Depression.

Koo J, Marangell LB, Nakamura M, Armstrong A, Jeon C, Bhutani T, Wu JJ.

J Eur Acad Dermatol Venereol. 2017 Jul 6. doi: 10.1111/jdv.14460. [Epub ahead of print] Review.

PMID:
28681405
2.

Is the Noradrenergic Symptom Cluster a Valid Construct in Adjunctive Treatment of Major Depressive Disorder?

Stauffer VL, Liu P, Goldberger C, Marangell LB, Nelson C, Gorwood P, Fava M.

J Clin Psychiatry. 2017 Mar;78(3):317-323. doi: 10.4088/JCP.15m09972.

PMID:
27685842
3.

Treatment discontinuation and tolerability as a function of dose and titration of duloxetine in the treatment of major depressive disorder.

Harada E, Shirakawa O, Satoi Y, Marangell LB, Escobar R.

Neuropsychiatr Dis Treat. 2016 Jan 11;12:89-97. doi: 10.2147/NDT.S86598. eCollection 2016.

4.

Comparison of antidepressant classes and the risk and time course of suicide attempts in adults: propensity matched, retrospective cohort study.

Valuck RJ, Libby AM, Anderson HD, Allen RR, Strombom I, Marangell LB, Perahia D.

Br J Psychiatry. 2016 Mar;208(3):271-9. doi: 10.1192/bjp.bp.114.150839. Epub 2015 Dec 3.

5.

Multimodal functional and structural neuroimaging investigation of major depressive disorder following treatment with duloxetine.

Fu CH, Costafreda SG, Sankar A, Adams TM, Rasenick MM, Liu P, Donati R, Maglanoc LA, Horton P, Marangell LB.

BMC Psychiatry. 2015 Apr 14;15:82. doi: 10.1186/s12888-015-0457-2.

6.

Impact of non-remission of depression on costs and resource utilization: from the COmorbidities and symptoms of DEpression (CODE) study.

Dennehy EB, Robinson RL, Stephenson JJ, Faries D, Grabner M, Palli SR, Stauffer VL, Marangell LB.

Curr Med Res Opin. 2015 Jun;31(6):1165-77. doi: 10.1185/03007995.2015.1029893. Epub 2015 May 12.

PMID:
25879140
7.

Efficacy comparison of duloxetine and SSRIs at doses approved in Japan.

Harada E, Schacht A, Koyama T, Marangell LB, Tsuji T, Escobar R.

Neuropsychiatr Dis Treat. 2015 Jan 12;11:115-23. doi: 10.2147/NDT.S72642. eCollection 2015.

8.

A double-blind, placebo-controlled study of edivoxetine as an adjunctive treatment for patients with major depressive disorder who are partial responders to selective serotonin reuptake inhibitor treatment.

Ball S, Dellva MA, D'Souza DN, Marangell LB, Russell JM, Goldberger C.

J Affect Disord. 2014;167:215-23. doi: 10.1016/j.jad.2014.06.006. Epub 2014 Jun 14.

PMID:
24995890
9.

Impact of fatigue on outcome of selective serotonin reuptake inhibitor treatment: secondary analysis of STAR*D.

Ferguson M, Dennehy EB, Marangell LB, Martinez J, Wisniewski SR.

Curr Med Res Opin. 2014 Oct;30(10):2109-18. doi: 10.1185/03007995.2014.936553. Epub 2014 Jul 4.

PMID:
24949937
10.

Clinical and functional outcomes of patients who experience partial response to citalopram: secondary analysis of STAR*D.

Dennehy EB, Marangell LB, Martinez J, Balasubramani GK, Wisniewski SR.

J Psychiatr Pract. 2014 May;20(3):178-87. doi: 10.1097/01.pra.0000450317.76117.62.

PMID:
24847991
11.

The relationship between change in apathy and changes in cognition and functional outcomes in currently non-depressed SSRI-treated patients with major depressive disorder.

Rothschild AJ, Raskin J, Wang CN, Marangell LB, Fava M.

Compr Psychiatry. 2014 Jan;55(1):1-10. doi: 10.1016/j.comppsych.2013.08.008. Epub 2013 Oct 24.

PMID:
24268564
12.

Relationship between major depressive disorder and associated painful physical symptoms: analysis of data from two pooled placebo-controlled, randomized studies of duloxetine.

Robinson MJ, Sheehan D, Gaynor PJ, Marangell LB, Tanaka Y, Lipsius S, Ohara F, Namiki C.

Int Clin Psychopharmacol. 2013 Nov;28(6):330-8. doi: 10.1097/YIC.0b013e328364381b.

PMID:
23873291
13.

Brain-derived neurotrophic factor in generalized anxiety disorder: results from a duloxetine clinical trial.

Ball S, Marangell LB, Lipsius S, Russell JM.

Prog Neuropsychopharmacol Biol Psychiatry. 2013 Jun 3;43:217-21. doi: 10.1016/j.pnpbp.2013.01.002. Epub 2013 Jan 10.

PMID:
23313564
14.

Comprehensive review of factors implicated in the heterogeneity of response in depression.

Carter GC, Cantrell RA, Victoria Zarotsky, Haynes VS, Phillips G, Alatorre CI, Goetz I, Paczkowski R, Marangell LB.

Depress Anxiety. 2012 Apr;29(4):340-54. doi: 10.1002/da.21918. Review.

PMID:
22511365
15.

Apathy in currently nondepressed patients treated with a SSRI for a major depressive episode: outcomes following randomized switch to either duloxetine or escitalopram.

Raskin J, George T, Granger RE, Hussain N, Zhao GW, Marangell LB.

J Psychiatr Res. 2012 May;46(5):667-74. doi: 10.1016/j.jpsychires.2012.02.010. Epub 2012 Mar 10.

PMID:
22410206
16.

Predictors of remission with placebo using an integrated study database from patients with major depressive disorder.

Nelson JC, Zhang Q, Deberdt W, Marangell LB, Karamustafalioglu O, Lipkovich IA.

Curr Med Res Opin. 2012 Mar;28(3):325-34. doi: 10.1185/03007995.2011.654010. Epub 2012 Jan 31.

PMID:
22292447
17.

Assessment of depressive symptoms and functional outcomes in patients with major depressive disorder treated with duloxetine versus placebo: primary outcomes from two trials conducted under the same protocol.

Oakes TM, Myers AL, Marangell LB, Ahl J, Prakash A, Thase ME, Kornstein SG.

Hum Psychopharmacol. 2012 Jan;27(1):47-56. doi: 10.1002/hup.1262. Epub 2012 Jan 13.

PMID:
22241678
18.

A pragmatic 12-week, randomized trial of duloxetine versus generic selective serotonin-reuptake inhibitors in the treatment of adult outpatients in a moderate-to-severe depressive episode.

Martinez JM, Katon W, Greist JH, Kroenke K, Thase ME, Meyers AL, Edwards SE, Marangell LB, Shoemaker S, Swindle R.

Int Clin Psychopharmacol. 2012 Jan;27(1):17-26. doi: 10.1097/YIC.0b013e32834ce11b.

PMID:
22027844
19.

A randomized placebo-controlled trial of duloxetine in patients with major depressive disorder and associated painful physical symptoms.

Gaynor PJ, Gopal M, Zheng W, Martinez JM, Robinson MJ, Marangell LB.

Curr Med Res Opin. 2011 Oct;27(10):1849-58. doi: 10.1185/03007995.2011.609539. Epub 2011 Aug 12.

PMID:
21838411
20.

Duloxetine versus placebo in the treatment of major depressive disorder and associated painful physical symptoms: a replication study.

Gaynor PJ, Gopal M, Zheng W, Martinez JM, Robinson MJ, Hann D, Marangell LB.

Curr Med Res Opin. 2011 Oct;27(10):1859-67. doi: 10.1185/03007995.2011.609540. Epub 2011 Aug 12.

PMID:
21838410

Supplemental Content

Loading ...
Support Center